Karen L. Houseknecht, B.S., M.S., Ph.D.
药理学教授
研究和奖学金副教务长
Location
Dr. Houseknecht的职业生涯, 它跨越了学术和企业研究环境, has focused on her unwavering passion around the discovery and development of novel therapeutics, 包括制药, biologic and nutritional therapies for the treatment of metabolic disorders such as diabetes and obesity.
Dr. Houseknecht's current research is focused on 1) identifying mechanisms underlying endocrine and metabolic side effects of antipsychotic medications and the implications of off-label prescribing of these medications to vulnerable populations such as children and the elderly; 2) new therapeutic/drug discovery and development; and 3) identifying mechanistic links between the regulation of mood and metabolism, 并应用于情绪障碍的治疗, sleep disorders, 肥胖和糖尿病. 实验室的探索性项目包括探索药物代谢的新机制, 对骨髓腔室特别感兴趣. Dr. Houseknecht's NIH funded research involves student researchers both at the undergraduate and graduate levels.
Prior to joining UNE, Karen served as Vice President of Global Research and Development at ASDI, Inc., 一家为客户提供产品和服务的跨国制药公司, biotech, 学术和非政府组织研究部门. At ASDI, Karen was the chief scientist and was responsible for developing and executing the global scientific strategy for the company as well as managing the global chemistry, analytical, 和DMPK学科. She also led efforts devoted to building and managing scientific business partnerships in the academic and NGO research partners.
在ASDI任职之前，Karen在Pfizer, Inc .领导药物发现研究团队., 最近担任副研究员, 糖尿病药物的发现, 心血管科, 代谢和内分泌疾病. Karen is the author of over 50 scientific publications and patents and has also served as Assistant professor of Endocrinology and Metabolism, 普渡大学医学兼职助理教授, 印第安纳大学医学院. In 1998, Karen served as Honorary Visiting Professor of Clinical Medicine at the Karolinska Hospital in Stockholm, Sweden.
In 1994, Karen accepted a position as Research Fellow at Harvard Medical School in the Department of Endocrinology and Metabolism, Beth Israel Hospital, Boston. There Karen's research focused on elucidating the mechanisms of insulin action using transgenic mouse technology to better understand the pathology of diabetes and obesity. 凯伦还参与了对新发现的肥胖激素的首批研究, leptin. 在哈佛大学期间，Karen获得了美国国家科学基金会的研究奖学金.S. 来支持她的糖尿病研究.
在她的职业生涯中, Karen has been an advocate for women in science and has served as a scientific mentor both in academia and the pharmaceutical industry. She is the recipient of the 2005 Power of Women Award for her work supporting educational and leadership opportunities for women and girls. In 2006, Karen was awarded the Women of Innovation Award for Large Business Innovation and Leadership by the CT Technology Council and was elected to the National Board of Directors for the Association of Women in Science (AWIS). Karen被康奈尔大学授予2007年杰出校友奖, 农业与生命科学学院, 制药行业的领导地位, 倡导妇女和女童权益, 以及对康奈尔大学使命的支持. Most recently, Karen was recognized by the Connecticut Womens Hall of Fame as one of the best of "A New Century of Women in Science".
Credentials
Education
博士后训练
贝斯以色列医院/哈佛医学院(波士顿，马萨诸塞州)
Research
Current research
Dr Houseknecht's research program lies at the interface of neuroscience and endocrinology/metabolism. 无论是研究药物滥用还是非典型抗精神病药物(SGAs), her research focuses on the pharmacology underlying mechanisms of action and mechanisms of adverse events (safety), particularly central nervous system regulation of whole-body energy metabolism (including diabetes). 豪斯内克特博士的工作还特别关注新的治疗发现, leading pharmacology and drug metabolism efforts to enhance drug target identification/validation and lead development
选定的出版物
Houseknecht, K.L., Bouchard, C.C. and Black, C.A. 2017. Mini-Review: Elucidating the mechanism(s) underlying antipsychotic and antidepressant-mediated fractures. J. Mental Health & 临床心理学1:9-13.
Motyl, K.J., Beauchemin, M., Barlow, D., Le, P.T., Nagano, K., Treyball, A., Contractor, A., Baron, R., Rosen, C.J. and Housenecht, K.L. 2017. A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice. Bone 103:168-176.
McLane, V.D, Bergquist, I., Cormier, J., Barlow, D.J., Houseknecht, K.L., Bilsky, E.J. and Cao, L. 2017. Long-term morphine delivery via slow release morphine pellets and osmotic pump: Serum concentration, analgesia, 以及纳洛酮引起的戒断. Life Sciences 185:1-7.
Motyl, K.J., DeMambro, V.E., Barlow, D., Olshan, D., Nagano, K., Baron, R., Rosen, C.J. and Houseknecht, K.L. 2015. 心得安可减轻雌鼠利培酮所致的骨质流失. Endocrinology 156:2374-83.
Caglic, D., Krutein, M., Bompiani, K., Barlow, D., Benoni, G., Pelletier, J., Reitz, A., Lairson, L, Houseknecht, K., Smith, G. and Dickerson, T. 2014. 临床可行的肉毒杆菌神经毒素A轻链喹啉类抑制剂的鉴定. J. Med. Chem. 57:669-76.
Aarde, S., Angrish, D., Barlow, D., Wright, M., Vandewater, S., Houseknecht, K., Dickerson, T. and Taffe, M. 2013. Mephedrone (4-methylmethcathinone) supports intravenous self administration in Sprague-Dawley and Wistar rats. Addiction Biology 18:786-799.
Miller, M.L., Creehan, K.M., Angrish, D., Barlow, D.J., Houseknecht, K.L., Dickerson, T.J. and Taffe, M.A. 2013. Changes in ambient temperature differentially alter the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). 毒品和酒精依赖. 127:248-253
Motyl, K.J., de Paula, I.D., Maloney, A.E., Lotinun, S., Bornstein, S., de Paula, F.J.A., Baron, R., Houseknecht, K.L. and Rosen, C.J. 2012. Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. Bone 50:490498.
黄，P-K，阿德，S.M., Angrish, D., Houseknecht, K.L., Dickerson, T.J., Taffe, M.A. 2012. d-甲基苯丙胺的对比效果, 3,4-methylenedioxymethamphetamine, 3,4 methylenedioxypyrovalerone, 以及4-甲基甲硫酮对大鼠车轮活性的影响. 毒品和酒精依赖. 126:168-175.
Wright, M.J. Jr, angish D, Aarde S. M., Barlow D. J., Buczynski, M. W., Creehan, K. M., Vandewater, S. A., Parsons, L. H., Houseknecht, K. L., Dickerson, T. J. and Taffe, M .A. 2012. 环境温度对体温调节和运动刺激作用的影响 of 4-威斯达和斯普拉格的甲基甲卡西酮-dawley rats. PLoS One. 7(8):e44652. Epub 2012 Aug 31.
DeNinno, M.P., Wright, S.W., Etienne, J.B., Olson, T.V., Rocke, B.N., Corbett, J.W., Kung, D.W., DiRico, K.J., Andrews, K.M., Millham, M. L., Parker, J.C., Esler, W., van Volkenburg, M., Boyer, D.D., Houseknecht, K.L. and Doran, S.D. 2012. Discovery of triazolopyrimdinebased PDE8B inhibitors: Exceptionally ligand-efficient and lipophilic ligand-efficient compounds. Bioorg. Med. Chem. Lett. doi: http://dx.doi.org/10.1016/j.bmcl.2012.06.079.
DeNinno, M.P., Wright, S.W., Visser, M.S., Etienne, J.B., Moore, D., Olson, T., Rocke, B., Sacdalan, M., Zarbo, C., Millham, M., Doran, S. and Houseknecht, K. 2011. 1,5-Substiuted nipecotic amides: Selective PDE8 inhibitors displaying diastereomer-dependent microsomal stability. Bioorg. Med. Chem. Lett. 21:3095-3098.
Capek, P., Zhang, Y., Barlow, D., Houseknecht, K., Smith, G. and Dickerson, T. 2011. Enhancing the pharmacokinetic properties of Botulinum neurotoxin serotype A protease inhibitors through rational design. ACS Chem. Neurosci. DOI: 10.1021/cn200021q
Torres, T.P., Fujimoto, Y., Donahue, E.P., Prinz, R.L., Houseknecht, K.L., Treadway, J.L. and Shiota M. 2011. Defective glycogenesis partially contributes toward the inability to suppress hepatic glucose production in response to hyperglycemia and hyperinuslinemia in Zucker Diabetic Fatty Rats. Diabetes 60:2225-33.
Millham, M., Zavadoski, W., Treadway, J., Houseknecht, K., and Gibbs, M. 2008. DGAT, 与三酰基甘油合成有关的基因, 在与代谢综合征相关的组织中是否有差异表达. OBESITY 16:S97-S98.
Houseknecht, K.L., Robertson, A.S., Zavadoski, W. Gibbs, E.M., Johnson, D.E. and Rollema, H. 2007. Acute effects of atypical antipsychotics on whole body insulin resistance in rats: Implications for adverse metabolic effects. 神经精神药理学 32:289-297.
Carvalho, E., Schellhorn, S.E., Zabolotny, J.M., Martin, S., Tozzo, E., Peroni, O.D., Houseknecht, K.L., Mundt, A., James, D.E. and Kahn, B.B. 2004. GLUT4 over-expression or deficiency in adipocytes of transgenic mice alters the composition of GLUT4 vesicles and the sub-cellular localization of GLUT4 and IRAP. J. Biol. Chem. 279:21598-21605.
Research interests
Dr. Houseknecht's research interests focus on the discovery of novel therapeutics for the treatment of diseases associated with metabolic syndrome